SITUATION IN NUMBERS
total (new) cases in last 24 hours
372 757 confirmed (39 827)
16 231 deaths (1722)
Western Pacific Region
96 580 confirmed (943)
3502 deaths (29)
195 511 confirmed (24 087)
10 189 deaths (1447)
South-East Asia Region
1990 confirmed (214)
65 deaths (7)
Eastern Mediterranean Region
27 215 confirmed (1840)
1877 deaths (136)
Region of the Americas
49 444 confirmed (12 428)
565 deaths (100)
1305 confirmed (315)
26 deaths (3)
WHO RISK ASSESSMENT
Global Level Very High
• Four new countries/territories/areas from the South-East Asia Region , and Region of the Americas  have reported cases of COVID-19.
• WHO has delivered a new shipment of emergency medical supplies to the Islamic Republic of Iran as part of COVID-19 response measures. Details can be found on the WHO Regional Office for the Eastern Mediterranean here.
• The WHO WhatsApp Health Alert has now attracted 10 million users since launching Friday, and the COVID-19 Solidarity Response Fund has raised more than US$70 million, in just 10 days. The media briefing can be found here.
• WHO and FIFA launched a joint campaign to equip the football community to tackle COVID-19. This awareness campaign calls on all people around the world to follow the five key steps to stop the spread of the disease. More information can be found here.
• WHO and its partners are constantly working to strengthen the chains of essential COVID-19 supplies. As global demand rises, WHO and its partners aim to ensure assistance to areas most in need. More information can be found in Subject in Focus.
SUBJECT IN FOCUS: Infection Prevention and Control (IPC) – update
With the emergence of COVID-19 virus, many uncertainties remain as to certain epidemiological, seroepidemiological (related to identifying antibodies in the population), clinical and virological characteristics of the virus and associated disease. Studies to assess these characteristics in different settings are critical to furthering our understanding. They will also provide robust information needed to refine forecasting models and inform public health measures.
As such, WHO, in collaboration with technical partners, has adapted early epidemiological investigations protocols from pandemic influenza and from MERS-CoV, to better understand these characteristics and how they may be used to inform public health measures.
To date, five early seroepidemiological core protocols and data collection forms are available on the WHO COVID-19 Technical guidance website.
All protocols propose a standardized methodology to allow data and biological samples to be systematically collected, taking into consideration local setting and outbreak characteristics, and shared rapidly in a format that can be easily aggregated, tabulated and analyzed across many different settings globally.
The latest protocol, the Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection, is intended to provide key epidemiological and serologic characteristics of COVID-19 virus in the general population. Specifically, data from this protocol will provide critical information about the extent of infection (as measured by the presence of antibodies in study subjects) in the general population, age-specific infection cumulative incidence, and the fraction of people with asymptomatic or subclinical infection.
The results of these investigations, whether individually or pooled across study sites/countries, will allow further understanding and provide robust estimates of key clinical, epidemiological and virological characteristics of the COVID-19 virus, including:
• Key epidemiological parameters, such as: secondary infection rate and secondary clinical attack rate of COVID-19 infection among close contacts, asymptomatic fraction of infection, serial interval and incubation period of COVID-19, the basic reproduction number of COVID-19 infection
• Clinical presentation of COVID-19 infection and course of associated disease
• Risk factors for transmission and infection, and identification of possible routes of transmission
• Impact of infection prevention and control measures in health care settings
• Serological response following symptomatic COVID-19 infection
• Age-stratified seroprevalence of antibodies against COVID-19 virus
• Cumulative incidence of infection, including extent of age-specific infection
• Infection and disease-severity ratios (case-hospitalization ratio [CHR] and case-fatality ratio [CFR])
• Viral load and shedding profiles
• Viral persistence on surfaces
To date, 13 countries across five of the six WHO regions, including both high-income and low-and middle-income countries, have begun to implement at least one of the early investigation protocols. A further 18 countries have signaled their intention to implement one of the protocols. WHO will continue to support countries in their epidemiological investigations through the provision of clear and comprehensive protocols.
RECOMMENDATIONS AND ADVICE FOR THE PUBLIC
If you are not in an area where COVID-19 is spreading or have not traveled from an area where COVID-19 is spreading or have not been in contact with an infected patient, your risk of infection is low.
It is understandable that you may feel anxious about the outbreak. Get the facts from reliable sources to help you accurately determine your risks so that you can take reasonable precautions.
Seek guidance from WHO, your healthcare provider, your national public health authority or your employer for accurate information on COVID-19 and whether COVID-19 is circulating where you live.
It is important to be informed of the situation and take appropriate measures to protect yourself and your family.
If you are in an area where there are cases of COVID-19 you need to take the risk of infection seriously.
Follow the advice of WHO and guidance issued by national and local health authorities. For most people, COVID-19 infection will cause mild illness however, it can make some people very ill and, in some people, it can be fatal.
Older people and those with pre-existing medical conditions (such as cardiovascular disease, chronic respiratory disease or diabetes) are at risk for severe disease.